Pharmena S.A. (PHR.WA)
PLN 4.0
(-3.15%)
PLN 4.0
(-3.15%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 24.13 Million PLN | 91.84% |
| 2022 | 12.57 Million PLN | 12.81% |
| 2021 | 11.15 Million PLN | 1.84% |
| 2020 | 10.95 Million PLN | -6.73% |
| 2019 | 11.74 Million PLN | 72.57% |
| 2018 | 6.8 Million PLN | -38.73% |
| 2017 | 11.1 Million PLN | -22.26% |
| 2016 | 14.28 Million PLN | -5.77% |
| 2015 | 15.15 Million PLN | -10.12% |
| 2014 | 16.86 Million PLN | -17.97% |
| 2013 | 20.55 Million PLN | 77.38% |
| 2012 | 11.58 Million PLN | -35.8% |
| 2011 | 18.05 Million PLN | 7.32% |
| 2010 | 16.81 Million PLN | -1.6% |
| 2009 | 17.09 Million PLN | 3.48% |
| 2008 | 16.51 Million PLN | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 23.87 Million PLN | -1.06% |
| 2024 Q2 | 13.56 Million PLN | -43.19% |
| 2023 Q2 | 52.06 Million PLN | 304.37% |
| 2023 Q1 | 12.87 Million PLN | 2.36% |
| 2023 Q4 | 24.13 Million PLN | -8.02% |
| 2023 Q3 | 26.23 Million PLN | -49.61% |
| 2023 FY | 24.13 Million PLN | 91.84% |
| 2022 Q3 | 63.53 Million PLN | 507.98% |
| 2022 Q1 | 10.33 Million PLN | -7.34% |
| 2022 FY | 12.57 Million PLN | 12.81% |
| 2022 Q4 | 12.57 Million PLN | -80.2% |
| 2022 Q2 | 10.45 Million PLN | 1.14% |
| 2021 Q2 | 11.82 Million PLN | -5.23% |
| 2021 Q4 | 11.15 Million PLN | -6.22% |
| 2021 FY | 11.15 Million PLN | 1.84% |
| 2021 Q1 | 12.47 Million PLN | 13.95% |
| 2021 Q3 | 11.89 Million PLN | 0.56% |
| 2020 Q3 | 11.67 Million PLN | 4.02% |
| 2020 Q4 | 10.95 Million PLN | -6.24% |
| 2020 Q2 | 11.22 Million PLN | 2.16% |
| 2020 Q1 | 10.99 Million PLN | -6.38% |
| 2020 FY | 10.95 Million PLN | -6.73% |
| 2019 Q3 | 13.68 Million PLN | -13.77% |
| 2019 Q1 | 14.47 Million PLN | 112.79% |
| 2019 Q4 | 11.74 Million PLN | -14.22% |
| 2019 FY | 11.74 Million PLN | 72.57% |
| 2019 Q2 | 15.87 Million PLN | 9.64% |
| 2018 Q2 | 9.19 Million PLN | -5.06% |
| 2018 FY | 6.8 Million PLN | -38.73% |
| 2018 Q4 | 6.8 Million PLN | -35.55% |
| 2018 Q3 | 10.55 Million PLN | 14.79% |
| 2018 Q1 | 9.68 Million PLN | -12.76% |
| 2017 Q4 | 11.1 Million PLN | 7.11% |
| 2017 Q3 | 10.36 Million PLN | -9.77% |
| 2017 Q1 | 12.71 Million PLN | -10.96% |
| 2017 FY | 11.1 Million PLN | -22.26% |
| 2017 Q2 | 11.48 Million PLN | -9.66% |
| 2016 Q1 | 12.91 Million PLN | -14.82% |
| 2016 Q2 | 13.39 Million PLN | 3.77% |
| 2016 Q4 | 14.28 Million PLN | 4.19% |
| 2016 FY | 14.28 Million PLN | -5.77% |
| 2016 Q3 | 13.7 Million PLN | 2.33% |
| 2015 Q2 | 17.16 Million PLN | 3.3% |
| 2015 Q1 | 16.62 Million PLN | -1.44% |
| 2015 FY | 15.15 Million PLN | -10.12% |
| 2015 Q4 | 15.15 Million PLN | -14.57% |
| 2015 Q3 | 17.74 Million PLN | 3.34% |
| 2014 Q2 | 17.48 Million PLN | -11.16% |
| 2014 FY | 16.86 Million PLN | -17.97% |
| 2014 Q4 | 16.86 Million PLN | -3.9% |
| 2014 Q3 | 17.54 Million PLN | 0.34% |
| 2014 Q1 | 19.68 Million PLN | -4.24% |
| 2013 Q1 | - PLN | -100.0% |
| 2013 FY | 20.55 Million PLN | 77.38% |
| 2013 Q3 | 21.16 Million PLN | 0.0% |
| 2013 Q4 | 20.55 Million PLN | -2.88% |
| 2012 FY | 11.58 Million PLN | -35.8% |
| 2012 Q4 | 11.58 Million PLN | 0.0% |
| 2011 FY | 18.05 Million PLN | 7.32% |
| 2010 FY | 16.81 Million PLN | -1.6% |
| 2009 FY | 17.09 Million PLN | 3.48% |
| 2008 FY | 16.51 Million PLN | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Bioceltix S.A. | 12.73 Million PLN | -89.489% |
| BIOTON S.A. | 822.22 Million PLN | 97.065% |
| Captor Therapeutics Spolka Akcyjna | 97.29 Million PLN | 75.197% |
| Mabion S.A. | 208.25 Million PLN | 88.412% |
| Molecure S.A. | 168.57 Million PLN | 85.685% |
| NanoGroup S.A. | 8.63 Million PLN | -179.578% |
| Poltreg S.A. | 127.09 Million PLN | 81.013% |
| Pure Biologics Spólka Akcyjna | 22.73 Million PLN | -6.131% |
| Ryvu Therapeutics S.A. | 403.2 Million PLN | 94.015% |
| Synthaverse S.A. | 265.9 Million PLN | 90.925% |
| Urteste S.A. | 29.59 Million PLN | 18.467% |